Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diffuse large B-cell lymphoma (DLBCL)
Pharma
ASH: Lilly defends survival data blemish in novel BTK trial win
The overall survival analysis created a bit of a problem for Lilly as the hazard ratio edged above 1 in favor of control.
Angus Liu
Dec 9, 2024 5:45pm
EU signs off on Regeneron's T-cell engager for 2 blood cancers
Aug 26, 2024 10:35am
Inconsistent survival data dent Roche's Columvi win in 2L DLBCL
Jun 16, 2024 5:32pm
Genmab to expand in New Jersey in bid to boost Epkinly rollout
Mar 28, 2024 4:29pm
CAR-T hype faces infrastructure reality check
Jan 15, 2024 3:00am
ASH: Roche offers glimpse at Columvi-Polivy combo in DLBCL
Dec 11, 2023 7:00am
